Orange, CANCT07628634Now EnrollingIRB Ready

Adenocarcinoma Clinical Trial in Orange, CA

Access cutting-edge adenocarcinoma treatment through this clinical trial at a research site in Orange. Study-provided care at no cost to qualified participants.

Sponsored by University of California, Irvine

Quick Self-Assessment

See if you qualify for this Orange location

Preparing your pre-screening questions…

Expert Care in Orange

Access adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related adenocarcinoma treatment provided free

Apply for This Orange Location

Check if you qualify for this adenocarcinoma clinical trial in Orange, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Orange

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Orange site if eligible
  4. 4Begin participation

About This Adenocarcinoma Study in Orange

This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

Sponsor: University of California, Irvine

Who Can Participate

Inclusion Criteria

Age: Subjects must be 18 years of age or older.
Diagnosis: Has a diagnosis of metastatic, recurrent, or unresectable solid tumors.
Life Expectancy: Subjects must have an expected life expectancy of at least 3 months.
Performance Status: Subjects must have an ECOG performance status of 0-2.
Organ Function: Subjects must have adequate organ function, as determined by the investigator through review of standard labs.
Pregnancy and Contraception: Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days prior to study enrollment and must agree to use adequate contraception throughout the study period and for 30 days after the last dose of study treatment. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.
Dietary Compliance: Subjects must be willing and able to comply with the methionine-reduced diet as prescribed by the study protocol.
Informed Consent: Subjects or Legally Authorized Representatives (LAR) must provide written informed consent prior to any study-specific procedures, indicating that they understand the purpose of the study and are willing to comply with its requirements.
Able to receive systemic standard of care cancer therapy. Additional criteria specifically for the glioma population:
Diagnosis: Histopathological proven diagnosis: a) newly diagnosed grade 2-3 glioma or b) all grades for recurrent glioma.
Treatment: Subjects must be able to receive radiation therapy and/or chemotherapy as a part of their treatment.

Exclusion Criteria

Brain Metastases: Subjects with uncontrolled or symptomatic brain metastases. Subjects with brain metastases that have been treated, are asymptomatic, and patients who require steroids are eligible.
Significant Clinical Illness: Subjects with uncontrolled significant clinical illnesses, including but not limited to: a) Active infections requiring systemic therapy. b) Severe cardiovascular conditions such as recent myocardial infarction (within 6 months), uncontrolled angina, congestive heart failure (NYHA class III or IV), or significant arrhythmias. (c) Uncontrolled diabetes.
Significant Amino Acid/Metabolic Illnesses: Subjects with severe or inherited illnesses that affect metabolism of amino acids or disrupt nutrient absorption, including but not limited to: a) Severe liver disease, such as cirrhosis or severe hepatic insufficiency, that may have compromised ability to metabolize amino acids. b) Inherited metabolic disorders, such as homocystinuria or other disorders affecting sulfur amino acid metabolism, that may have potential metabolic imbalances. c) Severe gastrointestinal disorders, such as active inflammatory bowel disease (IBD), short bowel syndrome, or other conditions that significantly impair nutrient absorption, that may lead to nutritional deficiencies and gastrointestinal complications.
Recent Surgery: Major surgery within 4 weeks of randomization (biopsies are acceptable per investigator judgement)
Concurrent Malignancies: Subjects with another malignancy that requires active treatment during the study period or is expected to interfere with the study intervention.
Pregnancy or Lactation: Female subjects who are pregnant or breastfeeding.
Malnutrition: Subjects with severe malnutrition or significant nutritional deficiencies per investigator's discretion.
Substance Abuse: Subjects with a history of substance abuse or dependency within the past 6 months that, in the opinion of the investigator, would interfere with adherence to study requirements.
Subjects with chronic kidney disease with advanced stages 3b or higher.
Psychiatric Disorders: Subjects with psychiatric disorders that would interfere with the ability to give informed consent or adhere to study requirements per investigator judgment.
Subjects with known allergies or intolerances to low-methionine foods.
Subjects with any medical or surgical conditions that, in the opinion of the investigator, would make adherence to the methionine-reduced diet unsafe or impractical.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orange?

Yes, this clinical trial (NCT07628634) has an active research site in Orange, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Adenocarcinoma Treatment Options in Orange, CA

If you're searching for adenocarcinoma treatment options in Orange, CA, this clinical trial (NCT07628634) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orange research site is actively enrolling participants for this clinical trial. You'll receive care from experienced adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Orange, CA

See all lung cancer clinical trials recruiting in Orange — not just this study.

Browse Lung Cancer Trials in Orange →

Browse More Trials by Condition

Lung Cancer TrialsProstate Cancer TrialsPancreatic Cancer TrialsStomach Cancer TrialsEsophageal Cancer TrialsNon-Small Cell Lung Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Orange?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Orange, CA